Eli Lilly’s retatrutide delivers 28.7% average weight loss—up to 71 pounds—in a Phase III trial.
Story Highlights
- Retatrutide achieved an unprecedented 28.7% weight loss at highest dose after 68 weeks in adults with obesity and knee osteoarthritis.
- 39% of participants lost 30% or more body weight; 24% lost 35% or more, surpassing dual-agonist drugs like tirzepatide.
- The trial reduced knee pain by up to 75.8% and improved physical function, addressing dual crises of obesity and joint issues.
- Triple-agonist mechanism targets GLP-1, GIP, and glucagon for superior fat metabolism and energy expenditure.
- Common side effects include nausea and diarrhea, typical of the drug class, with full data pending FDA review.
TRIUMPH-4 Trial Delivers Breakthrough Results
Eli Lilly announced topline results from the Phase III TRIUMPH-4 trial in late 2025. The study enrolled adults with obesity or overweight and knee osteoarthritis. At the highest dose, participants lost an average 28.7% of body weight, equivalent to 71.2 pounds over 68 weeks. Mid-dose achieved 26.4% loss, compared to 2.1% in the placebo group. This marks Lilly’s first Phase III success for retatrutide, confirming statistical significance on weight loss endpoints.
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trialhttps://t.co/h0m7tnolxk
— Joyce Adams (@JoyceSAdams) December 11, 2025
Triple Agonist Outpaces Competitors
Retatrutide, or LY3437943, activates GLP-1, GIP, and glucagon receptors. This triple mechanism enhances fat metabolism beyond dual agonists like tirzepatide, which averaged 22% loss in prior trials. Phase II data from 2023 showed up to 24% loss, setting the stage for TRIUMPH trials targeting obesity, osteoarthritis, sleep apnea, and liver disease. TRIUMPH-4 specifically addressed knee osteoarthritis, where obesity exacerbates joint pain for millions.
The drug reduced knee osteoarthritis pain by up to 75.8% and boosted physical function scores. Placebo groups saw minimal changes. Gastrointestinal side effects like nausea and diarrhea occurred more frequently than placebo, aligning with incretin-based therapies. Full adverse event details await congress presentations.
Watch:
Got a health question? Ask our AI doctor instantly, it’s free.
Development Builds on Proven Successes
Retatrutide stems from mid-2010s advances in gut hormone mimetics. Eli Lilly built on tirzepatide’s approval as Mounjaro for diabetes and Zepbound for weight loss, which generated over $5 billion quarterly. The GLP-1 market boomed to $20 billion-plus in 2024 sales, led by Novo Nordisk’s semaglutide at about 15% loss. Retatrutide’s glucagon addition drives faster, higher losses rarely exceeding 25-35% thresholds.
Phase III launched in 2024 after promising Phase II results. Additional TRIUMPH trials continue for broader indications. FDA approval could arrive by 2026-2027, expanding access for over 100 million obese US adults and 30 million with osteoarthritis.
Impacts Empower Patients and Strain Payers
Patients stand to gain dual benefits: substantial weight reduction and pain relief, potentially cutting comorbidities like diabetes and heart disease. Lilly projects blockbuster revenue exceeding $10 billion annually, boosting stock and market share. Competitors including Novo Nordisk face pressure as multi-agonists spur innovation races.
Short-term effects include supply challenges in a crowded field. Long-term, higher efficacy norms could lower obesity-related healthcare costs. Payers grapple with monthly prices around $1,000, amid Medicare coverage debates. Socially, this advances personal responsibility in health, aligning with conservative values of self-reliance over endless government intervention.
Chat safely, anytime, with My Healthy Doc.
Sources:
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial (PharmExec)
Lilly’s three-pronged drug puts obesity field ‘on notice’ (BioPharma Dive)
New weight loss drug dubbed ‘triple’ shows promise (ABC News)
Major weight loss, pain relief seen in Eli Lilly’s next-gen drug late-stage trial (Fox Business)
